VIKAS WSP LTD
RESULTS FOR Q3 FY 2017-18
Q E DECEMBER 2017
VIKAS WSP has declared GOOD RESULTS for the third
quarter ending December 2017. The company is progressing steadily in respect of
TOP LINE (SALES) an BOTTOM LINE (NET PROFIT) from quarter to quarter in the
last 5 quarters. The Latest quarter (Q3) also shows good improvement.
The various reports in recent past from the Management
indicate that its products are receiving good acceptance and good orders.
The Segment wise Revenue particulars enclosed to the results
indicate that Sales are increasing in respect of all areas like USA, Europe and
Domestic. Margins are also improving well. It will be interesting to watch its
further progress, as its products are now receiving good acceptance (and good
orders) outside India as well.
The
results are as below :
VIKAS
WSP
|
DEC'17
|
Sep '17
|
Dec '16
|
YOY
|
QOQ
|
Net
Sales
|
178.25
|
164.4
|
19.19
|
828.87
|
8.42
|
TOTAL
EXP
|
172.1
|
160.7
|
50.52
|
240.66
|
7.09
|
Interest
|
10.08
|
11.13
|
10.96
|
-8.03
|
-9.43
|
P/L
Before Tax
|
6.15
|
5.34
|
-31.22
|
219.7
|
15.17
|
Tax
|
-1.82
|
-1.73
|
-0.26
|
600
|
5.2
|
Net
Profit
|
7.97
|
7.07
|
-30.96
|
225.74
|
12.73
|
Equity
|
19.44
|
19.44
|
13.74
|
41.48
|
0
|
Basic
EPS
|
0.41
|
0.37
|
-2.25
|
218.22
|
10.81
|
Diluted
EPS
|
0.41
|
0.37
|
-1.9
|
221.58
|
10.81
|
MP
|
15.65
|
||||
PE
|
9.54
|
DETAILS
|
PRESENT
|
WHAT
IF ANALYSIS
|
||
QTRLY
EPS
|
0.41
|
0.41
|
(IF)
0.6
|
(IF)
0.6
|
MARKET
PRICE
|
16
|
(IF)
25
|
(IF)
25
|
36
|
P.E.RATIO
|
9.76
|
15.24
|
10.42
|
(IF)
15
|
This
"what if analysis shows" that a price of 25 to 36 is easily possible for Vikas
WSP, if the quarterly EPS rises at the same old (past) rate of growth to 0.6.
In all cases, a very reasonable PE ratio is assumed. So, Good days seem to be ahead for Vikas WSP.
The Management commentary on the company's performance and its future progress is very impressive and eloquent in the recent past. So are the orders inflow.
Note : This does not constitute a BUY / SELL / HOLD recommendation.
*
* * E N D * * *
No comments:
Post a Comment